Clinical Research Directory
Browse clinical research sites, groups, and studies.
Comparison of the Role of Losartan Alone vs Hydrochlorothiazide Plus Losartan
Sponsor: RESnTEC, Institute of Research
Summary
Losartan, an angiotensin II receptor blocker, has already been established as a treatment for diabetic nephropathy due to its ability to reduce blood pressure and mitigate the progression of kidney damage. However, the addition of a diuretic like hydrochlorothiazide may offer synergistic benefits in reducing proteinuria by addressing both the underlying renal pathology and potential volume overload in these patients. The current study aims at determining and comparing the role of losartan alone vs hydrochlorothiazide plus losartan in reducing proteinuria in diabetic nephropathy patients.
Official title: Comparison of the Role of Losartan Alone vs Hydrochlorothiazide Plus Losartan on Proteinuria in Diabetic Nephropathy Patients
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
234
Start Date
2024-08-01
Completion Date
2025-07-31
Last Updated
2024-07-09
Healthy Volunteers
No
Conditions
Interventions
Losartan
Patients will receives Losartan (LS) 50 mg per day.
Losartan + Hydrochlorothiazide
Patients will be given Losartan LS (50 mg per day) and Hydrochlorothiazide (HCTZ) 12.5 mg per day as a combination therapy.
Locations (1)
Medical department, Bahawal Victoria Hospital
Bahawalpur, Punjab Province, Pakistan